Meridian Bioscience, a diagnostic testing solutions provider, has applied for Emergency Use Authorisation (EUA) from the US Food and Drug Administration (FDA) for its SARS-CoV-2 molecular diagnostic test on the Revogene® platform. The test can detect the SARS-CoV-2 virus among individuals in 47 minutes and can be integrated in any laboratory or health system.
Bluejay Diagnostics and Toray Industries have entered into a collaborative agreement to develop a minimally invasive, point-of-care test to assess the progress of Covid-19 in high-risk patients. The Symphony™ IL-6 combines microfluidics and nanotechnology to create point-of-care tests in liquid biopsies.
ixlayer, a healthtech solutions provider, announced that its technology has been selected for a Community Alliance to Test Coronavirus at Home (CATCH) Study initiated by the Chan Zuckerberg Biohub and Stanford University. The study intends to conduct large-scale research on the testing and tracking of Covid-19 in the greater San Francisco Bay Area.
CorVent Medical has received EUA from the FDA for its RESPOND-19™ ventilator, which is able to be used by multiple patients. This new category of ventilators is designed for expanding critical care ventilation capacity to hospitals struggling with increasing number of Covid-19 patients suffering from acute respiratory distress syndrome (ARDS). The respiratory system is cost effective, reusable for multiple patients, and is commercially available in the US.